APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing Masao OmataTatsuo KandaShiv Kumar Sarin Guidelines Open access 26 May 2016 Pages: 681 - 701
APASL consensus statements and recommendation on treatment of hepatitis C Masao OmataTatsuo KandaShiv Kumar Sarin Guidelines Open access 29 April 2016 Pages: 702 - 726
HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy Geoffrey DusheikoBo WangIvana Carey Editorial 31 May 2016 Pages: 727 - 729
Targeting the renin–angiotensin system in liver fibrosis Pau Sancho-BruPere Ginès Editorial 31 May 2016 Pages: 730 - 732
The role of bile salts in liver regeneration Liyanne F. M. van de LaarschotPeter L. M. JansenSteven W. M. Olde Damink Review Article Open access 05 April 2016 Pages: 733 - 740
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals Che C. ColpittsThomas F. Baumert Review Article 05 April 2016 Pages: 741 - 748
Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review Dinesh JothimaniSanjay GovilMohamed Rela Review Article 23 June 2016 Pages: 749 - 761
Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise G. LiamisT. D. FilippatosM. S. Elisaf Review Article 21 June 2016 Pages: 762 - 772
New approaches for fibrosis regression in alcoholic cirrhosis Wajahat MehalUyen To Review Article 26 July 2016 Pages: 773 - 778
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure Fabien ZoulimJolanta Białkowska-WarzechaHarry L. A. Janssen Original Article 20 May 2016 Pages: 779 - 788
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients Dong JiGuo-Feng ChenGeorge Lau Original Article 21 July 2016 Pages: 789 - 798
A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment Yuko TakamiSusumu EguchiHideki Saitsu Original Article Open access 04 February 2016 Pages: 799 - 806
Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis Hong ZangFangfang LiuShaojie Xin Original Article 02 August 2016 Pages: 807 - 818
Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review Gaeun KimJuyoung KimSoon Koo Baik Original Article 22 February 2016 Pages: 819 - 828
HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes Tien Huey LimEdward GaneChris Cunningham Original Article 08 March 2016 Pages: 829 - 837
End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients Joseph AhnTaft BhuketRobert J. Wong Original Article 24 May 2016 Pages: 838 - 846
